April 2024 Publications
- Perspectives on development and advancement of new tuberculosis vaccines. da Costa C, Benn CS, Nyirenda T, Mpabalwani E, Grewal HMS, Ahmed R, Kapata N, Nyasulu PS, Maeurer M, Hui DS, Goletti D, Zumla A. Int J Infect Dis. 2024 Apr. doi: 10.1016/j.ijid.2024.106987. Epub 2024 Feb 26.
- Comparative transcriptomics reveals common and strain-specific responses of human macrophages to infection with Mycobacterium tuberculosis and Mycobacterium bovis BCG. Li P, Li Y, Wang CC, Xia LG. Microb Pathog. 2024 Apr. doi: 10.1016/j.micpath.2024.106593. Epub 2024 Feb 20.
- Perspectives on development and advancement of new tuberculosis vaccines. da Costa C, Benn CS, Nyirenda T, Mpabalwani E, Grewal HMS, Ahmed R, Kapata N, Nyasulu PS, Maeurer M, Hui DS, Goletti D, Zumla A. Int J Infect Dis. 2024 Apr. doi: 10.1016/j.ijid.2024.106987. Epub 2024 Feb 26.
- An Immunoinformatics-Based Study of Mycobacterium tuberculosis Region of Difference-2 Uncharacterized Protein (Rv1987) as a Potential Subunit Vaccine Candidate for Preliminary Ex Vivo Analysis. Arega AM, Dhal AK, Pattanaik KP, Nayak S, Mahapatra RK. Appl Biochem Biotechnol. 2024 Apr. doi: 10.1007/s12010-023-04658-9. Epub 2023 Jul 27.
- From antigens to immune responses: Shaping the future of TB detection and prevention. Panda S, Kearns K, Cheng C, Lindestam Arlehamn CS. Int J Infect Dis. 2024 Apr. doi: 10.1016/j.ijid.2024.106983. Epub 2024 Feb 26.
- Alemnew Dagnew-developing a new TB vaccine. Kazi F, Mushtaq A. Lancet Infect Dis. 2024 Apr. doi: 10.1016/S1473-3099(24)00163-4.
- Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial. Tait D, Diacon A, Borges ÁH, van Brakel E, Hokey D, Rutkowski KT, Hunt DJ, Russell M, Andersen PL, Kromann I, Ruhwald M, Churchyard G, Dawson R. J Infect Dis. 2024 Apr 1. doi: 10.1093/infdis/jiae170. Epub ahead of print.
- In vitro evaluation of the binding activity of novel mouse IgG1 opsonic monoclonal antibodies to Mycobacterium tuberculosis and other selected mycobacterial species. Nyazema KB, Shey BA, Sei CJ, Peters RPH, Maningi NE, Fischer GW, Bernard Fourie P. J Clin Tuberc Other Mycobact Dis. 2024 Apr 1. doi: 10.1016/j.jctube.2024.100435.
- Intrinsic immunogenicity of liposomes for tuberculosis vaccines: Effect of cationic lipid and cholesterol. Szachniewicz MM, Neustrup MA, van Meijgaarden KE, Jiskoot W, Bouwstra JA, Haks MC, Geluk A, Ottenhoff THM. Eur J Pharm Sci. 2024 Apr 1. doi: 10.1016/j.ejps.2024.106730. Epub 2024 Feb 20.
- Momentum of hope: The journey toward a universal TB vaccine. Gulumbe BH, Shehu A. Trop Doct. 2024 Apr 2. doi: 10.1177/00494755241244833. Epub ahead of print.
- Inhaled aerosol viral-vectored vaccines against tuberculosis. Stylianou E, Satti I. Curr Opin Virol. 2024 Apr 3. doi: 10.1016/j.coviro.2024.101408. Epub ahead of print.
- Estimating the Potential Public Health Value of BCG Revaccination. Clark RA, Sumner T, Weerasuriya CK, Bakker R, Scriba TJ, White RG. J Infect Dis. 2024 Apr 3. doi: 10.1093/infdis/jiae089. Epub ahead of print.
- Production and Evaluation of Ag85B:HspX:hFcγ1 Immunogenicity as an Fc Fusion Recombinant Multi-Stage Vaccine Candidate Against Mycobacterium tuberculosis. Karbalaei M, Mosavat A, Soleimanpour S, Farsiani H, Ghazvini K, Amini AA, Sankian M, Rezaee SA. Curr Microbiol. 2024 Apr 4. doi: 10.1007/s00284-024-03655-3.
- Multi-omics analysis reveals that linoleic acid metabolism is associated with variations of trained immunity induced by distinct BCG strains. Xu JC, Chen ZY, Huang XJ, Wu J, Huang H, Niu LF, Wang HL, Li JH, Lowrie DB, Hu Z, Lu SH, Fan XY. Sci Adv. 2024 Apr 5. doi: 10.1126/sciadv.adk8093. Epub 2024 Apr 5.
- Coverage of BCG Vaccination for children aged until 7 years old and its determinants in French Guiana. Wang Q, Nacher M, Tosi A, Clarke L, Rwagitinywa J, Alsibai KD, Castor MJ. J Epidemiol Popul Health. 2024 Apr. doi: 10.1016/j.jeph.2024.202381. Epub 2024 Apr 4.
- HtpG-A Major Virulence Factor and a Promising Vaccine Antigen against Mycobacterium tuberculosis. Berisio R, Barra G, Napolitano V, Privitera M, Romano M, Squeglia F, Ruggiero A. Biomolecules. 2024 Apr 11. doi: 10.3390/biom14040471.
- The causes and consequences of trained immunity in myeloid cells. Bhargavi G, Subbian S. Front Immunol. 2024 Apr 11. doi: 10.3389/fimmu.2024.1365127.
- Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial. Lopez Ramon R, Wilkie M, Ramos Lopez F, Riste M, Wright D, Peralta Alvarez MP, Williams N, Morrison H, Stylianou E, Folegatti P, Jenkin D, Vermaak S, Rask L, Cabrera Puig I, Powell Doherty R, Lawrie A, Moss P, Hinks T, Bettinson H, McShane H. Lancet Infect Dis. 2024 Apr 12. doi: 10.1016/S1473-3099(24)00143-9. Epub ahead of print.
- Cell-Mediated Immune Response Against Mycobacterium tuberculosis and Its Potential Therapeutic Impact. Khanna H, Gupta S, Sheikh Y. J Interferon Cytokine Res. 2024 Apr 12. doi: 10.1089/jir.2024.0030. Epub ahead of print.
- A new tool for accelerating tuberculosis vaccine development. Jeyanathan M, Xing Z. Lancet Infect Dis. 2024 Apr 12. doi: 10.1016/S1473-3099(24)00178-6. Epub ahead of print.
- Lipids Extracted from Mycobacterial Membrane and Enveloped PLGA Nanoparticles for Encapsulating Antibacterial Drugs Elicit Synergistic Antimicrobial Response against Mycobacteria. Pu X, Wang Y, Wang X, Sang X, Jiang M, Qi D, Zhao X, Chen R, Li J, Liu X, Liu Z, Yang J. Mol Pharm. 2024 Apr 15. doi: 10.1021/acs.molpharmaceut.3c01001. Epub ahead of print.
- Immune responses induced by Mycobacterium tuberculosis heat-resistant antigen (Mtb-HAg) upon co-administration with Bacillus Calmette-Guérin in mice. Guo F, Wei J, Song Y, Song J, Wang Y, Li K, Li B, Qian Z, Wang X, Wang H, Xu T. Cytokine. 2024 Apr 17. doi: 10.1016/j.cyto.2024.156610. Epub ahead of print.
- A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice. Shaku MT, Um PK, Ocius KL, Apostolos AJ, Pires MM, Bishai WR, Kana BD. Elife. 2024 Apr 19. doi: 10.7554/eLife.89157. Epub ahead of print.
- Genomic Interactions Between Mycobacterium tuberculosis and Humans. Palittapongarnpim P, Tantivitayakul P, Aiewsakun P, Mahasirimongkol S, Jaemsai B. Annu Rev Genomics Hum Genet. 2024 Apr 19. doi: 10.1146/annurev-genom-021623-101844. Epub ahead of print.
- Recombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals’ blood cells in combination with CpG-DNA. Ozeki Y, Yokoyama A, Nishiyama A, Yoshida Y, Ohara Y, Mashima T, Tomiyama C, Shaban AK, Takeishi A, Osada-Oka M, Yamaguchi T, Tateishi Y, Maeyama JI, Hakamata M, Moro H, Kikuchi T, Hayashi D, Suzuki F, Yamamoto T, Iho S, Katahira M, Yamamoto S, Matsumoto S. Sci Rep. 2024 Apr 21. doi: 10.1038/s41598-024-58836-8.
- Research Progress on Liposome Pulmonary Delivery of Mycobacterium tuberculosis Nucleic Acid Vaccine and Its Mechanism of Action. Zhang D, Zhao H, Li P, Wu X, Liang Y. J Aerosol Med Pulm Drug Deliv. 2024 Apr 26. doi: 10.1089/jamp.2023.0025. Epub ahead of print.
- A new neonatal BCG vaccination pathway in England: a mixed methods evaluation of its implementation. Jones K, Chisnall G, Crocker-Buque T, Elliman D, Horwood J, Mounier-Jack S, Campbell CN, Saliba V, Chantler T. BMC Public Health. 2024 Apr 26. doi: 10.1186/s12889-024-18586-8.
- Realising the potential of correlates of protection for vaccine development, licensure and use: short summary. King DF, Groves H, Weller C, Jones I, Cramer JP, Gilbert PB, Goldblatt D, Gruber MF, Kampmann B, Maïga D, Pasetti MF, Plotkin SA, Precioso A, Wassie L, Wittke F, Kaslow DC. NPJ Vaccines. 2024 Apr 29. doi: 10.1038/s41541-024-00872-6.